Abstract
Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and GNAQ have been identified in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi, respectively. These mutations are likely to play a critical role in driving nevogenesis. While each mutation is able to activate the MAP kinase pathway, they also interact with a host of different proteins in other pathways. The different melanocytic developmental pathways activated by each mutation cause the cells to migrate, proliferate, and differentiate to different extents within the skin. This causes each mutation to give rise to a characteristic growth pattern. The exact location and differentiation state of the cell of origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that most of the same developmental pathways are also present in melanoma.
| Original language | English |
|---|---|
| Article number | 463184 |
| Journal | Dermatology Research and Practice |
| Volume | 2011 |
| DOIs | |
| State | Published - Jan 1 2011 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Molecular nevogenesis. / Ross, Andrew L.; Sanchez, Margaret I.; Grichnik, James M.
In: Dermatology Research and Practice, Vol. 2011, 463184, 01.01.2011.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Molecular nevogenesis
AU - Ross, Andrew L.
AU - Sanchez, Margaret I.
AU - Grichnik, James M
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and GNAQ have been identified in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi, respectively. These mutations are likely to play a critical role in driving nevogenesis. While each mutation is able to activate the MAP kinase pathway, they also interact with a host of different proteins in other pathways. The different melanocytic developmental pathways activated by each mutation cause the cells to migrate, proliferate, and differentiate to different extents within the skin. This causes each mutation to give rise to a characteristic growth pattern. The exact location and differentiation state of the cell of origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that most of the same developmental pathways are also present in melanoma.
AB - Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and GNAQ have been identified in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi, respectively. These mutations are likely to play a critical role in driving nevogenesis. While each mutation is able to activate the MAP kinase pathway, they also interact with a host of different proteins in other pathways. The different melanocytic developmental pathways activated by each mutation cause the cells to migrate, proliferate, and differentiate to different extents within the skin. This causes each mutation to give rise to a characteristic growth pattern. The exact location and differentiation state of the cell of origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that most of the same developmental pathways are also present in melanoma.
UR - http://www.scopus.com/inward/record.url?scp=84861481682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861481682&partnerID=8YFLogxK
U2 - 10.1155/2011/463184
DO - 10.1155/2011/463184
M3 - Article
AN - SCOPUS:84861481682
VL - 2011
JO - Dermatology Research and Practice
JF - Dermatology Research and Practice
SN - 1687-6105
M1 - 463184
ER -